Dr. Neal I. Muni

Dr. Neal I. Muni is a highly accomplished life sciences executive with 25 years of industry experience as an operator, investor, and advisor to various biotechnology and pharmaceutical companies. He currently serves as the Managing Director of RTK Group, a biopharmaceutical advisory and investment fund. Before joining RTK Group, Dr. Muni held the CEO position at Azurity Pharmaceuticals. Before his role at Azurity, he was the Head of Corporate Strategy at Sunovion Pharmaceuticals. Earlier in his career, he worked as an engagement manager at the healthcare investment bank Leerink Swann.

Additionally, Dr. Muni served as a Medical Officer in the FDA's Division of Cardiovascular Devices. He is also involved in academia, holding appointments at Harvard Medical School and Mass General Brigham as an Associate Physician in the Hospital Medicine Unit. Furthermore, he has been appointed as a visiting scholar at Harvard University’s Wyss Institute for Biologically Inspired Engineering. Dr. Muni earned his MD and MSPH from Tulane University School of Medicine, a BA in Business Economics and a B.Sc. in Biochemistry from Brown University.

Functional Expertise:
• Startup/Early Stage Business Tactics & Strategy
• Regulatory Approvals & Compliance (FDA)
• Product Development